Translation for reference purpose only |
Annual Securities Report
From April 1, 2022 to March 31, 2023
(The 146th Fiscal Year)
Takeda Pharmaceutical Company Limited
Translation for reference purpose only |
As used in this annual securities report, references to the "Company," "Takeda," "we," "us" and "our" are to Takeda Pharmaceutical Company Limited and, except as the context otherwise requires, its consolidated subsidiaries.
In this annual securities report, we present our audited consolidated financial statements as of March 31, 2022 and 2023 and for the fiscal years ended March 31, 2022 and 2023. Our consolidated financial statements are prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS"). The term IFRS also includes International Accounting Standards ("IAS") and the related interpretations of the committees (Standard Interpretations Committee and International Financial Reporting Interpretations Committee).
As used in this annual securities report, "ADS" means an American Depositary Share, representing 0.5 shares of the Company's common stock, and "ADR" means an American Depositary Receipt evidencing one or more ADSs.
As used in this annual securities report, except as the context otherwise requires, the "Companies Act" means the Companies Act of Japan.
Amounts shown in this annual securities report have been rounded to the nearest indicated digit unless otherwise specified. In tables and graphs with rounded figures, sums may not add up due to rounding.
Translation for reference purpose only |
TABLE OF CONTENTS | ||
2. | History | 4 |
3. | Description of Business | 6 |
4. | Overview of Subsidiaries and Associates | 8 |
5. | Employees | 11 |
II. Operating and Financial Review and Prospects | 13 | |
1. | Management Policy, Management Environment and Management Issues | 13 |
2. | Corporate Sustainability Policies and Initiatives | 18 |
3. | Risk Factors | 21 |
4. | Management's Analysis of Financial Position, Operating Results and Cash Flows | 24 |
5. Material Contracts | 39 | |
6. Research and Development | 39 | |
III. Property, Plant, and Equipment | 65 | |
1. | Overview of Capital Expenditures | 65 |
2. | Major Facilities | 65 |
3. | Plans for New Facility Construction, Old Facility Disposal, etc | 67 |
IV. Information on the Company | 68 | |
1. | Information on the Company's Shares | 68 |
2. | Acquisition of Treasury Stock and Other Related Status | 81 |
3. | Dividend Policy | 82 |
4. Corporate Governance | 83 | |
V. Financial Information | 113 | |
1. | Consolidated Financial Statements and Others | 114 |
2. | Unconsolidated Financial Statements and Others | 115 |
VI. Overview of Administrative Procedures for Shares of the Company | 133 | |
VII. Reference Information on the Company | 134 | |
Part 2. Information on Guarantors for Takeda | 135 | |
Independent Auditor's Report | ||
Internal Control Report | ||
Confirmation Letter |
[Cover]
[Document Filed]
[Applicable Law] [Filed with] [Filing Date] [Fiscal Year] [Company Name]
[Title and Name of Representative] [Address of Head Office]
[Telephone Number]
[Name of Contact Person]
[Nearest Place of Contact]
[Telephone Number] [Name of Contact Person] [Place for Public Inspection]
Translation for reference purpose only
Annual Securities Report
Article 24, paragraph 1 of the Financial Instruments and Exchange Act of Japan
Director, Kanto Local Finance Bureau
June 28, 2023
The 146th Fiscal Year (from April 1, 2022 to March 31, 2023)
Takeda Pharmaceutical Company Limited
Christophe Weber, Representative Director, President & Chief Executive Officer
1-1, Doshomachi 4-chome,Chuo-ku, Osaka
(The above address is the registered head office location and the ordinary business operations are conducted at the "Nearest Place of Contact")
Not applicable
Not applicable
1-1,Nihonbashi-Honcho2-chome,Chuo-ku, Tokyo
(Global Headquarters)
+81-3-3278-2111 (Main telephone number)
Norimasa Takeda, Chief Accounting Officer & Corporate Controller, Global Finance
Takeda Pharmaceutical Company Limited (Global Headquarters) (1-1, Nihonbashi Honcho 2-chome,Chuo-ku, Tokyo)
Stock Exchange, Inc.
(2-1, Nihonbashi Kabutocho, Chuo-ku, Tokyo)
Nagoya Stock Exchange, Inc.
(8-20, Sakae 3-chome,Naka-ku, Nagoya)
Fukuoka Stock Exchange
(14-2, Tenjin 2-chome,Chuo-ku, Fukuoka)
Sapporo Stock Exchange
(14-1, Minamiichijonishi 5-chome,Chuo-ku, Sapporo)
1
Table of ContentsTranslation for reference purpose only
Part 1. Information on Takeda
I. Overview of Takeda | ||||||||||
1. Key Financial Data | ||||||||||
(1) Consolidated Financial Data | ||||||||||
JPY (millions), unless otherwise indicated | ||||||||||
Fiscal Year | 142nd | 143rd | 144th | 145th | 146th | |||||
Year Ended | March 31, 2019 | March 31, 2020 | March 31, 2021 | March 31, 2022 | March 31, 2023 | |||||
Revenue | ¥ | 2,097,224 | ¥ | 3,291,188 | ¥ | 3,197,812 | ¥ | 3,569,006 | ¥ | 4,027,478 |
Profit (loss) before tax | 127,612 | (60,754) | 366,235 | 302,571 | 375,090 | |||||
Net profit for the year | 135,080 | 44,290 | 376,171 | 230,166 | 317,038 | |||||
Net profit attributable to owners of the | 135,192 | 44,241 | 376,005 | 230,059 | 317,017 | |||||
Company | ||||||||||
Total comprehensive income (loss) for the | 121,595 | (199,419) | 697,416 | 824,427 | 911,574 | |||||
year | ||||||||||
Total equity | 5,185,991 | 4,727,486 | 5,177,177 | 5,683,523 | 6,354,672 | |||||
Total assets | 13,792,773 | 12,821,094 | 12,912,293 | 13,178,018 | 13,957,750 | |||||
Equity attributable to owners of the | ||||||||||
Company per share (JPY) | 3,332.94 | 3,032.22 | 3,308.93 | 3,665.61 | 4,087.49 | |||||
Basic earnings per share (JPY) | 140.61 | 28.41 | 240.72 | 147.14 | 204.29 | |||||
Diluted earnings per share (JPY) | 139.82 | 28.25 | 238.96 | 145.87 | 201.94 | |||||
Ratio of equity attributable to owners of | 37.6 | 36.8 | 40.1 | 43.1 | 45.5 | |||||
the Company to total assets (%) | ||||||||||
Return on equity attributable to owners of | ||||||||||
the Company (%) | 3.8 | 0.9 | 7.6 | 4.2 | 5.3 | |||||
Price earnings ratio (Times) | 32.2 | 116.4 | 16.6 | 23.8 | 21.3 | |||||
Net cash from (used in) operating activities | 328,479 | 669,752 | 1,010,931 | 1,123,105 | 977,156 | |||||
Net cash from (used in) investing activities | (2,835,698) | 292,119 | 393,530 | (198,125) | (607,102) | |||||
Net cash from (used in) financing activities | 2,946,237 | (1,005,213) | (1,088,354) | (1,070,265) | (709,148) | |||||
Cash and cash equivalents at the end of the | ||||||||||
year | 702,093 | 637,614 | 966,222 | 849,695 | 533,530 | |||||
Number of employees (Number of persons) | 49,578 | 47,495 | 47,099 | 47,347 | 49,095 |
Notes:
- The consolidated financial statements have been prepared and presented in accordance with International Financial Reporting Standards (IFRS).
- All figures shown are rounded to the nearest million JPY.
2
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Takeda Pharmaceutical Co. Ltd. published this content on 28 June 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 June 2023 08:10:09 UTC.